ID   FHS049i-sh2633B
AC   CVCL_YY80
SY   iPSC - 2633B
DR   BioSample; SAMN06093565
DR   GEO; GSM2411827
DR   WiCell; fhs049i-sh2633b
DR   Wikidata; Q98126195
RX   PubMed=28388431;
CC   Part of: Framingham Heart Study (FHS) collection.
CC   Part of: Next Generation Genetic Association studies (Next Gen) program cell lines.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_YY81 ! FHS050i-sh2633D
SX   Female
AG   61-70Y
CA   Induced pluripotent stem cell
DT   Created: 02-07-20; Last updated: 29-06-23; Version: 7
//
RX   PubMed=28388431; DOI=10.1016/j.stem.2017.01.010;
RA   Warren C.R., O'Sullivan J.F., Friesen M., Becker C.E., Zhang X.-L.,
RA   Liu P.-C., Wakabayashi Y., Morningstar J.E., Shi X., Choi J., Xia F.,
RA   Peters D.T., Florido M.H.C., Tsankov A.M., Duberow E.A., Comisar L.,
RA   Shay J., Jiang X., Meissner A., Musunuru K., Kathiresan S.,
RA   Daheron L., Zhu J., Gerszten R.E., Deo R.C., Vasan R.S.,
RA   O'Donnell C.J., Cowan C.A.;
RT   "Induced pluripotent stem cell differentiation enables functional
RT   validation of GWAS variants in metabolic disease.";
RL   Cell Stem Cell 20:547-557.e7(2017).
//